Safety of intravenous recombinant tissue plasminogen activator for treatment of acute ischemic stroke: the Minnesota experience.
2011-08
Loading...
View/Download File
Persistent link to this item
Statistics
View StatisticsJournal Title
Journal ISSN
Volume Title
Title
Safety of intravenous recombinant tissue plasminogen activator for treatment of acute ischemic stroke: the Minnesota experience.
Authors
Published Date
2011-08
Publisher
Type
Thesis or Dissertation
Abstract
Background and Purpose
Intravenous recombinant tissue plasminogen activator (IV rt-PA) has been shown to reduce the likelihood of disability and death following an acute ischemic stroke by placebo-controlled, randomized clinical trials. We evaluated the safety of this treatment in routine clinical practice by analyzing frequencies and predictors of poor outcomes in patients treated within hospitals in Minnesota.
Methods
In a retrospective observational cohort study of 576 acute ischemic stroke patients treated with IV rt-PA from January 2008 to June 2010, we reviewed data from 21 hospitals contributing information on stroke admissions to the Minnesota Stroke Registry. We applied multivariate logistic regression to determine association of demographic characteristics, cardiovascular risk factors and stroke severity with symptomatic intracranial hemorrhage, serious systemic hemorrhage and inpatient death.
Results
Acute ischemic stroke patients administered IV rt-PA were slightly older than non-thrombolytic treatment patients and had significantly higher frequencies of atrial fibrillation, diabetes mellitus and medical history of previous stroke. 4.6% of IV rt-PA patients were diagnosed with symptomatic intracranial hemorrhage (sICH), 1.1% incurred systemic hemorrhage and 7.3% died during their hospitalization. In comparison, 4.7% of patients not treated with any rt-PA died in the hospital. After adjustment for demographic and clinical factors, significant predictors of sICH were National Institutes of Health Stroke Scale (NIHSS) Score OR: 1.14 (1.06 – 1.22), diabetes mellitus OR: 9.97 (1.32 – 75.21), dyslipidemia OR: 6.42 (1.35 – 30.51), hypertension OR: 5.57 (1.11 – 27.98) and medical history of a previous stroke OR: 5.32 (1.03 – 27.62). Higher NIHSS scores were associated with a greater risk of inpatient death. Intravenous thrombolysis 3 – 4.5 hours after stroke symptoms did not increase the risk for sICH or inpatient death when compared with IV rt-PA administration within 3 hours. Patients aged 80 years and older did not incur significantly different inpatient outcomes.
Conclusions
When compared to the frequencies of poor outcomes reported in clinical trials and previous observational studies, inpatient IV rt-PA clinical outcomes in Minnesota suggest this is a safe treatment. NIHSS Score, diabetes mellitus, dyslipidemia, hypertension and previous stroke are possible risk factors for post-thrombolytic cerebral hemorrhage.
Description
University of Minnesota M.S. thesis. August 2011. Major: Health services research, policy, and administration. Advisor: Robert L. Kane. 1 computer file (PDF) v, 22 pages.
Related to
Replaces
License
Series/Report Number
Funding information
Isbn identifier
Doi identifier
Previously Published Citation
Suggested citation
Manyara, Warren. (2011). Safety of intravenous recombinant tissue plasminogen activator for treatment of acute ischemic stroke: the Minnesota experience.. Retrieved from the University Digital Conservancy, https://hdl.handle.net/11299/117058.
Content distributed via the University Digital Conservancy may be subject to additional license and use restrictions applied by the depositor. By using these files, users agree to the Terms of Use. Materials in the UDC may contain content that is disturbing and/or harmful. For more information, please see our statement on harmful content in digital repositories.